OncotypeDx was designed to be used in patients who have been diagnosed with organ confined prostate cancer but are not quite sure if they need to seek definitive treatment or may undergo an active surveillance protocol with their health care provider. The OncotypeDx test was designed for individuals with low to intermediate grade prostate cancer (less than or equal to Gleason 3+4=7) who are uncertain if they should get treatment or pursue active surveillance.
The test looks at the activation of 17 specific genes (using specialized lab tests using your prostate cancer positive tissue taken during your previous biopsy) and, using an algorithm (special math test) is able to estimate a patient's likelihood of having favorable pathology. This algorithm utilizes a patient's risk using their National Comprehensive Cancer Network (NCCN) risk category (very low risk, low risk, intermediate risk) combined with the results of their 17 gene panel (known as the GPS score) to determine if further testing or treatment may be necessary for certain individuals in a specific risk category.
Patient Sample Report:
This page contains an interactive patient sample report. Hover your mouse over different parts of the form to learn what each particular section means.